HRP20171206T1 - Novi pripravci za liječenje amiotrofične lateralne skleroze - Google Patents
Novi pripravci za liječenje amiotrofične lateralne skleroze Download PDFInfo
- Publication number
- HRP20171206T1 HRP20171206T1 HRP20171206TT HRP20171206T HRP20171206T1 HR P20171206 T1 HRP20171206 T1 HR P20171206T1 HR P20171206T T HRP20171206T T HR P20171206TT HR P20171206 T HRP20171206 T HR P20171206T HR P20171206 T1 HRP20171206 T1 HR P20171206T1
- Authority
- HR
- Croatia
- Prior art keywords
- preparation
- use according
- salt
- extended
- release formulation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 11
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 title claims 5
- 238000013265 extended release Methods 0.000 claims 9
- 238000009472 formulation Methods 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 208000032319 Primary lateral sclerosis Diseases 0.000 claims 6
- 206010046298 Upper motor neurone lesion Diseases 0.000 claims 6
- 201000010901 lateral sclerosis Diseases 0.000 claims 6
- 208000005264 motor neuron disease Diseases 0.000 claims 6
- 201000002241 progressive bulbar palsy Diseases 0.000 claims 6
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 6
- 208000002320 spinal muscular atrophy Diseases 0.000 claims 6
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims 4
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 4
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims 4
- 229960004047 acamprosate Drugs 0.000 claims 4
- 229960000794 baclofen Drugs 0.000 claims 4
- 229960004181 riluzole Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 201000000196 pseudobulbar palsy Diseases 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 1
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229960005461 torasemide Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Lubricants (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (14)
1. Pripravak za uporabu u liječenju amiotrofične lateralne skleroze („ALS”) ili srodnih poremećaja koji je izabran od primarne lateralne skleroze (PLS), progresivne mišićne atrofije (PMA), pseudobulbarne paralize i progresivne bulbarne paralize (PBP) i frontalno-temporalne demencije (FTD), koji sadrži (i), akamprozat ili njegovu sol, ili njegov pripravak s produženim otpuštanjem, i (ii) baklofen, ili njegovu sol, ili njegovu formulaciju s produženim otpuštanjem.
2. Pripravak za uporabu prema zahtjevu 1, naznačen time da nadalje sadrži torasemid ili njegovu sol, ili njegovu formulaciju s produženim otpuštanjem.
3. Pripravak za uporabu prema zahtjevu 1 ili 2, naznačen time da nadalje sadrži riluzol, ili njegovu sol, ili njegovu formulaciju s produženim otpuštanjem.
4. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da nadalje sadrži farmaceutski prihvatljivi nosač ili pomoćno sredstvo.
5. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da su spojevi formulirani ili se primjenjuju zajedno, odvojeno ili sekvencijalno.
6. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da da se navedeni pripravak daje subjektu više puta.
7. Pripravak za uporabu prema bilo kojem od zahtjeva 3 do 6, naznačen time da se riluzol primjenjuje u dozi od 0.01 do 100 mg dnevno, poželjno od 0.1 do 50 mg dnevno.
8. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 7, naznačen time da se akamprosat primjenjuje u dozi od manjoj od 50 mg dnevno, poželjnije manje od 10 mg dnevno.
9. Pripravak za uporabu prema bilo kojem od zahtjeva 1 do 8, naznačen time da se baklofen primjenjuje u dozi od manjoj od 30 mg dnevno.
10. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni pripravak primjenjuje oralno.
11. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da se navedeni pripravak primjenjuje oralno i ponavljajuće svaki drugi dan, naizmjence s riluzolom.
12. Pripravak za uporabu prema bilo kojem od prethodnih zahtjeva, naznačen time da su spojevi formulirani zajedno.
13. Akamprosat, ili njegova sol, ili njegova formulacija s produženim otpuštanjem, za uporabu u kombinaciji s baklofenom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, u postupku za liječenje ALS ili srodnog poremećaja koji se bira od primarne lateralne skleroze (PLS), progresivne mišićne atrofije (PMA), pseudobulbarne paralize i progresivne bulbarne paralize (PBP) i frontalno-temporalne demencije (FTD).
14. Akamprosat, ili njegova sol, ili njegova formulacija s produženim otpuštanjem, za uporabu u kombinaciji s baklofenom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, te riluzolom, ili njegovom soli, ili njegovom formulacijom s produženim otpuštanjem, u postupku za liječenje ALS ili srodnog poremećaja koji se bira od primarne lateralne skleroze (PLS), progresivne mišićne atrofije (PMA), pseudobulbarne paralize i progresivne bulbarne paralize (PBP) i frontalno-temporalne demencije (FTD).
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2012/053565 WO2012117073A2 (en) | 2011-03-01 | 2012-03-01 | New compositions for treating neurological disorders |
| PCT/EP2012/053570 WO2012117076A2 (en) | 2011-03-01 | 2012-03-01 | Baclofen and acamprosate based therapy of neurogical disorders |
| EP13706548.8A EP2819664B1 (en) | 2012-03-01 | 2013-02-28 | New compositions for treating amyotrophic lateral sclerosis |
| PCT/EP2013/054024 WO2013127917A1 (en) | 2011-03-01 | 2013-02-28 | New compositions for treating amyotrophic lateral sclerosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171206T1 true HRP20171206T1 (hr) | 2017-10-20 |
Family
ID=47754536
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171206TT HRP20171206T1 (hr) | 2012-03-01 | 2017-08-07 | Novi pripravci za liječenje amiotrofične lateralne skleroze |
Country Status (12)
| Country | Link |
|---|---|
| EP (3) | EP3235498A1 (hr) |
| JP (1) | JP6158234B2 (hr) |
| CY (1) | CY1119195T1 (hr) |
| EA (1) | EA031331B9 (hr) |
| HR (1) | HRP20171206T1 (hr) |
| HU (1) | HUE034212T2 (hr) |
| LT (1) | LT2819664T (hr) |
| PL (1) | PL2819664T3 (hr) |
| PT (1) | PT2819664T (hr) |
| RS (1) | RS56175B1 (hr) |
| SI (1) | SI2819664T1 (hr) |
| UA (1) | UA114811C2 (hr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3151459A1 (en) * | 2019-09-20 | 2021-03-25 | Ana PEREIRA | Controlled release formulations of riluzole and their uses |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3180381B2 (ja) * | 1991-08-31 | 2001-06-25 | ウェルファイド株式会社 | 抗アルドステロン作用剤 |
| NZ589304A (en) * | 2008-04-29 | 2012-03-30 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| MX2010011880A (es) * | 2008-04-29 | 2011-05-25 | Pharnext | Nuevos enfoques terapeuticos para tratar la enfermedad del alzheimer y trastornos relacionados mediante una modulacion de la respuesta de estres celular. |
| CN102065898B (zh) * | 2008-04-29 | 2015-08-26 | 法奈科斯公司 | 通过调节血管发生治疗阿茨海默病和相关病症的新治疗手段 |
| EP2322163A1 (en) * | 2009-11-03 | 2011-05-18 | Pharnext | New therapeutics approaches for treating alzheimer disease |
| UA113165C2 (xx) * | 2011-03-01 | 2016-12-26 | Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат | |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| KR101918745B1 (ko) * | 2011-03-01 | 2018-11-15 | 파넥스트 | 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료 |
| EP2727587A1 (en) * | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
-
2013
- 2013-02-28 JP JP2014559213A patent/JP6158234B2/ja not_active Expired - Fee Related
- 2013-02-28 PT PT137065488T patent/PT2819664T/pt unknown
- 2013-02-28 EP EP17173296.9A patent/EP3235498A1/en not_active Withdrawn
- 2013-02-28 EP EP13706548.8A patent/EP2819664B1/en active Active
- 2013-02-28 UA UAA201410678A patent/UA114811C2/uk unknown
- 2013-02-28 LT LTEP13706548.8T patent/LT2819664T/lt unknown
- 2013-02-28 RS RS20170807A patent/RS56175B1/sr unknown
- 2013-02-28 SI SI201330727T patent/SI2819664T1/sl unknown
- 2013-02-28 PL PL13706548T patent/PL2819664T3/pl unknown
- 2013-02-28 EP EP18157222.3A patent/EP3348261B1/en active Active
- 2013-02-28 HU HUE13706548A patent/HUE034212T2/en unknown
- 2013-02-28 EA EA201400970A patent/EA031331B9/ru not_active IP Right Cessation
-
2017
- 2017-08-07 HR HRP20171206TT patent/HRP20171206T1/hr unknown
- 2017-08-08 CY CY20171100849T patent/CY1119195T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2819664A1 (en) | 2015-01-07 |
| EA031331B9 (ru) | 2019-02-28 |
| JP2015508797A (ja) | 2015-03-23 |
| JP6158234B2 (ja) | 2017-07-05 |
| HUE034212T2 (en) | 2018-02-28 |
| EP2819664B1 (en) | 2017-05-31 |
| EA031331B1 (ru) | 2018-12-28 |
| EP3235498A1 (en) | 2017-10-25 |
| PL2819664T3 (pl) | 2017-12-29 |
| CY1119195T1 (el) | 2018-02-14 |
| EP3348261B1 (en) | 2020-10-21 |
| PT2819664T (pt) | 2017-08-24 |
| EP3348261A1 (en) | 2018-07-18 |
| EA201400970A1 (ru) | 2015-02-27 |
| RS56175B1 (sr) | 2017-11-30 |
| LT2819664T (lt) | 2017-10-25 |
| UA114811C2 (uk) | 2017-08-10 |
| SI2819664T1 (sl) | 2017-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY187988A (en) | Composition for treating hyperlipidemia comprising oxyntomodulin derivative | |
| NZ700881A (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
| MX2022014313A (es) | Formulaciones para administracion oral de agentes activos con perfil de absorcion controlada. | |
| AU2016219643A1 (en) | Pharmaceutical combination for the treatment of pain | |
| MX347753B (es) | Formulaciones resistentes al abuso. | |
| NZ707551A (en) | Prostacyclin compositions and methods for using the same | |
| JP2013231087A5 (hr) | ||
| WO2012075081A3 (en) | High-strength testosterone undecanoate compositions | |
| UA109991C2 (xx) | Карбаматні сполуки, їх отримання і застосування | |
| MY156288A (en) | Pharmaceutical formulations containing dopamine receptor ligands. | |
| WO2015104292A3 (en) | Compounds for use in treating or preventing cancerous diseases | |
| WO2014117904A3 (en) | Oral care compositions | |
| BR112012019374A2 (pt) | composição farmacêutica, pellet de liberação prolongada, composição farmacêutica oral, método para tratamento de uma doença neurodegenerativa ou um dano ao sistema nervoso em um indivíduo necessitado do mesmo e método para preparação de uma formulação de liberação prolongada de um agente ativo | |
| NZ714273A (en) | Pharmaceutical composition comprising the combination of a biocompatible nanoparticle and a compound of interest, preparation and uses thereof | |
| RS52867B (en) | GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS | |
| MX357759B (es) | Formulaciones y formas de dosificacion de fosfolipidos oxidados. | |
| WO2010129962A3 (en) | Combination treatment of hydroxypyridonate actinide/lanthanide decorporation agents | |
| JP2014520856A5 (hr) | ||
| GB2523707A (en) | Novel pharmaceutical formulations and their use in the treatment of periodontal disease | |
| WO2014130691A3 (en) | Pharmaceutical formulations of nitrite and uses thereof | |
| MX2021010595A (es) | Composicion farmaceutica, preparacion y usos de la misma. | |
| SG10201907289VA (en) | Monomethylfumarate prodrug compositions | |
| HRP20171206T1 (hr) | Novi pripravci za liječenje amiotrofične lateralne skleroze | |
| BR112014031306A2 (pt) | composição farmacêutica e respectivos usos | |
| EP2891496A4 (en) | PHARMACEUTICAL COMPOSITION COMPRISING A COMPLEX EXTRACT OF AURANTII NOBILIS PERICARPIUM AND CRATAEGUS AS AN ACTIVE INGREDIENT IN THE TREATMENT OR PREVENTION OF OBESITY OR METABOLIC DISEASES OF LIPIDIC ORIGIN |